Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Procedures
>
Diagnostic Procedure
>
Echocardiography, Doppler, Color
Echocardiography, Doppler, Color
Echocardiography, Doppler, and Color Imaging: Cutting-Edge Techniques for Cardiovascular Research.
Echocardiography uses ultrasound waves to visualize the structure and function of the heart.
Doppler echocardiography measures blood flow velocity, while color Doppler imaging provides a visual representation of blood flow.
These advanced imaging modalities are essential tools for cardiovascular research, enabling researchers to optimize protocols, improve reproducibility, and take their studies to new heights.
Leverange the power of these techniques to enhance your research and drive scientific discovery.
Echocardiography uses ultrasound waves to visualize the structure and function of the heart.
Doppler echocardiography measures blood flow velocity, while color Doppler imaging provides a visual representation of blood flow.
These advanced imaging modalities are essential tools for cardiovascular research, enabling researchers to optimize protocols, improve reproducibility, and take their studies to new heights.
Leverange the power of these techniques to enhance your research and drive scientific discovery.
Most cited protocols related to «Echocardiography, Doppler, Color»
Biological Evolution
BLOOD
Echocardiography, Doppler
Echocardiography, Doppler, Color
ECHO protocol
Electricity
Endocardium
Epistropheus
Physical Examination
Strains
Transducers
Velocimetry
Abdomen
Adult
Child
Cholangiopancreatography, Magnetic Resonance
Choledochus
Contrast Media
Echocardiography, Doppler, Color
Electricity
Liver
Patients
Radiologist
Sedatives
Sequoia
Spleen
This prospective, single-center study enrolled 22 consecutive patients with symptomatic TR referred to University Hospital Campus Bio-Medico of Rome for TTVI consideration, between June 2020 and October 2021. Patients were included in the study only if they presented with TR that was at least severe, diagnosed by echocardiography, and underwent a cardiac CT study dedicated to the right chambers. Exclusion criteria were as follows: previous TV surgery, rheumatic TV disease, active endocarditis, congenital heart disease, and need of urgent cardiac surgery. Tricuspid regurgitation was assessed according to semi-quantitative echocardiographic color flow doppler evaluation [16 (link),17 (link)]. CT data were prospectively collected in the institutional medical imaging archiving server and retrospectively analyzed. The study protocol was approved by the local ethical committee with the name TRIMA (Tricuspid Regurgitation IMAging) study. All patients provided written consent for taking part to this study.
Congenital Heart Defects
Echocardiography
Echocardiography, Doppler, Color
Endocarditis
Heart
Operative Surgical Procedures
Patients
Rheumatism
Surgical Procedure, Cardiac
Tricuspid Valve Insufficiency
Procedural success was defined by device release in the appropriate position without embolization. Immediate complete closure was determined by angiography shortly after deployment of the device. TTE was performed 24 hours after intervention or prior to discharge to determine the occlusion status for every patient and considered for the outcome at discharge.
The residual shunt was classified as into trivial, small, moderate and large shunts. A trivial shunt was defined when the width of the color jet as assessed by color Doppler echocardiography as it exited the septum of <1 mm. Small, moderate, and large shunts were considered when the width of 1 to 2 mm, 3 to 4 mm, or width ≥4 mm, respectively [3 (link)].
A valve regurgitation was considered when persistent new or increased valvar regurgitation occurred after the procedure. A heart block was considered when there was a complete atrioventricular block or other persistent cardiac arrhythmia that required long-term medical treatment or pacemaker placement [3 (link)].
The residual shunt was classified as into trivial, small, moderate and large shunts. A trivial shunt was defined when the width of the color jet as assessed by color Doppler echocardiography as it exited the septum of <1 mm. Small, moderate, and large shunts were considered when the width of 1 to 2 mm, 3 to 4 mm, or width ≥4 mm, respectively [3 (link)].
A valve regurgitation was considered when persistent new or increased valvar regurgitation occurred after the procedure. A heart block was considered when there was a complete atrioventricular block or other persistent cardiac arrhythmia that required long-term medical treatment or pacemaker placement [3 (link)].
Angiography
Atrioventricular Block
Cardiac Conduction System Disease
Dental Occlusion
Echocardiography, Doppler, Color
Embolization, Therapeutic
Heart Block
Long-Term Care
Medical Devices
Pacemaker, Artificial Cardiac
Patient Discharge
Patients
Birth
Blood Circulation
Echocardiography
Echocardiography, Doppler, Color
Epistropheus
Infant
Infant, Newborn
Obstetric Delivery
Pulmonary Artery
Rate, Heart
Surgeons
Systole
Ultrasonography, Doppler, Pulsed
Valves, Pulmonary
Most recents protocols related to «Echocardiography, Doppler, Color»
Standard 2-dimensional Doppler echocardiography with color flow mapping was performed preoperatively in all patients. The severity of MR was semi-quantitatively assessed on a scale from mild to moderate and severe according to quantitative measurement of the effective regurgitant orifice area and regurgitant volume by using the proximal isovelocity surface area method.[10 (link)] In cases with an extremely eccentric jet, the vena contract width was measured in the parasternal long-axis view and measured using the zoom mode at the narrowest portion of the regurgitant jet.[10 (link)] The LA diameter was obtained using the biplane method of disks.[11 (link)] LV diameters were determined from parasternal long-axis acquisitions.[11 (link)] The LV ejection fraction was calculated by the modified biplane Simpson method.[11 (link)]
Echocardiography, Doppler, Color
Epistropheus
Patients
The detailed collection and processing of echocardiographic data have been described before. In accordance with the internationally accepted guidelines, each patient included in the study underwent transthoracic echocardiography (TTE) with color flow Doppler and tissue Doppler by board-certified cardiologists trained in echocardiography.
Cardiologists
Echocardiography
Echocardiography, Doppler, Color
Patients
Tissues
Patients diagnosed with CRC who underwent primary curative surgery were retrospectively included in a single center between Jan 2013 and Dec 2017. All patients were histologically diagnosed with CRC adenocarcinoma preoperatively. A total of 136 CRC patients with T2DM were included as the T2DM group. A total of 1143 CRC patients without T2DM were screened, and 136 patients were selected as the non-T2DM group by matching gender with T2DM group using propensity score matching (20 (link)). Color Doppler echocardiography, abdominal-enhanced computed tomography (CT) and plain chest CT were routinely performed as a part of the preoperative assessment. Other inclusion criteria included the following (1 (link)): age older than 18 (2 (link)); underwent primary curative surgery for CRC; and (3 (link)) no severe cardiopulmonary dysfunction. The exclusion criteria include (1 (link)): emergency surgery for gastrointestinal massive bleeding, obstruction or perforation (2 (link)); stage IV CRC (3 (link)); Non-R0 resection; and (4 (link)) incomplete medical record. Informed consent was obtained from each patient. This study was conducted in accordance with the World Medical Association Declaration of Helsinki, and approved by the Ethics Committee of our hospital (No.2022-RE-116).
Abdomen
Adenocarcinoma
Chest
Echocardiography, Doppler, Color
Emergencies
Ethics Committees, Clinical
Gastrointestinal Surgical Procedure
Gender
Operative Surgical Procedures
Patients
X-Ray Computed Tomography
As previously reported, the closure of oral ibuprofen for treating PDA is around 77.6%.20 Based on that study, it was estimated that the closure rate of oral ibuprofen is around 78%. This study adopted a non-inferiority design with α = 0.05 and 1-β = 0.80. The sample size ratio of the two groups was designed as 1:1. We used Pearson Chi-square test by SAS software (9.4) to calculate the sample size. The sample size of oral ibuprofen group and rectal dexibuprofen group is 95, respectively.
Inclusion criteria: Preterm infants with gestational age <34 weeks and color Doppler echocardiographic evidence of hemodynamically significant PDA (hs PDA) with systemic hypoperfusion was intended to be included into this study since January 2020. As of January 1, 2021, this trial had included 87 preterm infants who met the inclusion criteria. Here, we summarize the results of this phase into a pilot report. The included neonates were admitted to the neonatal intensive care unit (NICU) of Jiangsu Maternal and Child Health Hospital, Nanjing Medical University, which is a representative Grade III NICU in Jiangsu province, East of China. Exclusion criteria: Before medication, patients with abnormal coagulation function, intraventricular hemorrhage (IVH) ≥ grade III, non-hs PDA, urine output less than 1 mL/kg/hour for 24 consecutive hours, acute kidney injury, inherited metabolic diseases, duct-dependent congenital heart disease or major congenital anomalies were excluded. The written informed consent has been obtained from parents. Study protocol was approved by the Ethical Committee of Jiangsu Maternal and Child Health Hospital (Number: 202004037-1). This study conforms to CONSORT 2010 statement21 (link) with a checklist (Supplementary ).
A total of 812 preterm infants with PDA were hospitalized in our NICU after birth; 725 were excluded as showed in flow chart (Figure 1 ). Finally, 87 preterm infants were randomly assigned into two groups. Random number table method was used for randomization. Group one included 44 preterm newborns using oral ibuprofen, and group two included 43 preterm infants with dexibuprofen suppository (Figure 1 ).![]()
Inclusion criteria: Preterm infants with gestational age <34 weeks and color Doppler echocardiographic evidence of hemodynamically significant PDA (hs PDA) with systemic hypoperfusion was intended to be included into this study since January 2020. As of January 1, 2021, this trial had included 87 preterm infants who met the inclusion criteria. Here, we summarize the results of this phase into a pilot report. The included neonates were admitted to the neonatal intensive care unit (NICU) of Jiangsu Maternal and Child Health Hospital, Nanjing Medical University, which is a representative Grade III NICU in Jiangsu province, East of China. Exclusion criteria: Before medication, patients with abnormal coagulation function, intraventricular hemorrhage (IVH) ≥ grade III, non-hs PDA, urine output less than 1 mL/kg/hour for 24 consecutive hours, acute kidney injury, inherited metabolic diseases, duct-dependent congenital heart disease or major congenital anomalies were excluded. The written informed consent has been obtained from parents. Study protocol was approved by the Ethical Committee of Jiangsu Maternal and Child Health Hospital (Number: 202004037-1). This study conforms to CONSORT 2010 statement21 (link) with a checklist (
A total of 812 preterm infants with PDA were hospitalized in our NICU after birth; 725 were excluded as showed in flow chart (
Flow chart of this study.
Birth
Children's Health
Coagulation, Blood
Congenital Abnormality
Congenital Heart Defects
dexibuprofen
Echocardiography, Doppler, Color
Gestational Age
Hemorrhage
Ibuprofen
Infant, Newborn
Kidney Failure, Acute
Metabolic Diseases
Mothers
Parent
Patients
Pharmaceutical Preparations
Preterm Infant
Rectum
Suppositories
Urine
All the dogs underwent complete echocardiographic examination at Days − 15 and 180 by the same operator, including transthoracic 2D, M-mode and spectral and colour-flow Doppler echocardiographic evaluations using transducer arrays of 1–4 MHz and 3–8 MHz (ESAOTE, Italy).
Examinations were performed in conscious unsedated dogs during a period of quiet breathing, with the animals in left and right lateral recumbency. At least five consecutive cardiac cycles were acquired and stored for off-line measurements. A clinical scoring system was employed based on ultrasound findings, according to [6 (link), 24 (link), 25 (link)]. Briefly, pulsed wave (PW)-spectra signals for calculation of STIs were acquired from the right parasternal short axis view of the pulmonary artery with the sample volume at the valve level; the acceleration time (AT) of pulmonary artery (PA) flow was measured from the onset of the pulsed Doppler PA flow signal to peak flow velocity. The right ventricular ejection time (ET) was measured from the onset to the end of the Doppler PA flow signal; moreover, the AT/ET ratio was calculated. When tricuspid regurgitation and/or mitral regurgitation were present, CW spectra were acquired from the left apical cranial four-chamber views. Each dog was assigned a score from 0 to 3 for pulmonary hypertension, considering AT, ET, AT/ET and TRV [6 (link)].
Radiological and echocardiographic examinations were performed by two independent investigators that were blinded to dog identification and clinical and parasitological data.
Examinations were performed in conscious unsedated dogs during a period of quiet breathing, with the animals in left and right lateral recumbency. At least five consecutive cardiac cycles were acquired and stored for off-line measurements. A clinical scoring system was employed based on ultrasound findings, according to [6 (link), 24 (link), 25 (link)]. Briefly, pulsed wave (PW)-spectra signals for calculation of STIs were acquired from the right parasternal short axis view of the pulmonary artery with the sample volume at the valve level; the acceleration time (AT) of pulmonary artery (PA) flow was measured from the onset of the pulsed Doppler PA flow signal to peak flow velocity. The right ventricular ejection time (ET) was measured from the onset to the end of the Doppler PA flow signal; moreover, the AT/ET ratio was calculated. When tricuspid regurgitation and/or mitral regurgitation were present, CW spectra were acquired from the left apical cranial four-chamber views. Each dog was assigned a score from 0 to 3 for pulmonary hypertension, considering AT, ET, AT/ET and TRV [6 (link)].
Radiological and echocardiographic examinations were performed by two independent investigators that were blinded to dog identification and clinical and parasitological data.
Acceleration
Animals
Consciousness
Cranium
Echocardiography
Echocardiography, Doppler, Color
Epistropheus
Heart
Mitral Valve Insufficiency
Physical Examination
Pulmonary Artery
Pulmonary Hypertension
Sexually Transmitted Diseases
Transducers
Tricuspid Valve Insufficiency
Ultrasonography
Ultrasonography, Doppler, Pulsed
Ventricles, Right
X-Rays, Diagnostic
Top products related to «Echocardiography, Doppler, Color»
Sourced in Canada, United States, Japan
The Vevo 2100 is a high-resolution, real-time in vivo imaging system designed for preclinical research. It utilizes advanced ultrasound technology to capture detailed images and data of small animal subjects.
Sourced in United States, Norway, United Kingdom, Japan, France, Canada, Germany, Belgium
The Vivid 7 is a high-performance ultrasound system designed for cardiovascular and general imaging applications. It features advanced imaging technologies and versatile capabilities to support comprehensive diagnostic assessments.
Sourced in United States, Netherlands
The EPIC 7C is a laboratory instrument designed for conducting various analytical and measurement tasks. It is a compact and versatile device that can be used for a wide range of applications in research and development laboratories. The EPIC 7C is capable of performing precise measurements and data analysis, but a more detailed description of its core function and intended use is not available without the risk of introducing bias or extrapolation.
Sourced in United States
The Vivid echocardiographic system is a diagnostic imaging device designed for cardiac assessment. It utilizes advanced ultrasound technology to capture real-time images of the heart's structure and function.
Sourced in United States, Norway, United Kingdom, Japan
The Vivid E95 is a high-performance cardiovascular ultrasound system designed for comprehensive cardiac and vascular imaging. It features advanced technologies and a user-friendly interface.
Sourced in United States, Germany
Isoflurane is a volatile anesthetic agent used in medical settings. It is a clear, colorless, and nonflammable liquid that is vaporized and administered through inhalation to induce and maintain general anesthesia. Isoflurane is used to provide anesthesia during surgical procedures.
Sourced in United States, Japan
The Vivid S60N is a compact and portable ultrasound system designed for cardiovascular and general imaging applications. It features a high-resolution display and advanced imaging capabilities, providing healthcare professionals with the tools to perform a variety of diagnostic exams.
Sourced in Norway, United States, Italy, China
Vivid IQ is a portable cardiovascular ultrasound system developed by GE Healthcare. It is designed to provide high-quality, real-time imaging for cardiac and vascular assessments. The system integrates advanced imaging technologies to enable clinicians to obtain comprehensive diagnostic information.
More about "Echocardiography, Doppler, Color"
Echocardiography, also known as cardiac ultrasound, is a non-invasive imaging technique that uses high-frequency sound waves to create detailed images of the heart's structure and function.
This powerful diagnostic tool allows clinicians and researchers to visualize the heart's chambers, valves, and blood flow, providing critical insights into cardiovascular health.
One key advancement in echocardiography is Doppler imaging, which measures the velocity and direction of blood flow within the heart.
Doppler echocardiography, including continuous-wave Doppler, pulsed-wave Doppler, and color Doppler, enables researchers to assess parameters like cardiac output, valve function, and the presence of any abnormal blood flow patterns.
Color Doppler imaging takes this technology a step further by providing a visual representation of blood flow, using color-coded maps to indicate the direction and speed of blood movement.
This powerful technique is essential for evaluating complex cardiovascular conditions, such as valvular heart disease, congenital heart defects, and cardiomyopathies.
Researchers leveraging advanced echocardiographic systems like the Vevo 2100, Vivid 7, EPIC 7C, Vivid echocardiographic system, and Vivid E95 can optimize their protocols, improve reproducibility, and drive scientific discovery.
Paired with the use of anesthetic agents like Isoflurane gas, these state-of-the-art imaging modalities enable precise, high-resolution visualization of the cardiovascular system in animal models, allowing for groundbreaking insights and advancements in the field of cardiovascular research.
By harnessing the power of echocardiography, Doppler, and color imaging, researchers can take their studies to new heights, unlocking a deeper understanding of the heart's structure and function.
Whether using the Vivid S60N, Vivid IQ, or other cutting-edge systems, these techniques are essential tools for driving scientific progress and improving cardiovascular health.
This powerful diagnostic tool allows clinicians and researchers to visualize the heart's chambers, valves, and blood flow, providing critical insights into cardiovascular health.
One key advancement in echocardiography is Doppler imaging, which measures the velocity and direction of blood flow within the heart.
Doppler echocardiography, including continuous-wave Doppler, pulsed-wave Doppler, and color Doppler, enables researchers to assess parameters like cardiac output, valve function, and the presence of any abnormal blood flow patterns.
Color Doppler imaging takes this technology a step further by providing a visual representation of blood flow, using color-coded maps to indicate the direction and speed of blood movement.
This powerful technique is essential for evaluating complex cardiovascular conditions, such as valvular heart disease, congenital heart defects, and cardiomyopathies.
Researchers leveraging advanced echocardiographic systems like the Vevo 2100, Vivid 7, EPIC 7C, Vivid echocardiographic system, and Vivid E95 can optimize their protocols, improve reproducibility, and drive scientific discovery.
Paired with the use of anesthetic agents like Isoflurane gas, these state-of-the-art imaging modalities enable precise, high-resolution visualization of the cardiovascular system in animal models, allowing for groundbreaking insights and advancements in the field of cardiovascular research.
By harnessing the power of echocardiography, Doppler, and color imaging, researchers can take their studies to new heights, unlocking a deeper understanding of the heart's structure and function.
Whether using the Vivid S60N, Vivid IQ, or other cutting-edge systems, these techniques are essential tools for driving scientific progress and improving cardiovascular health.